About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The 2013 Nobel Prize in Chemistry | Main | A Leak at Lilly »

October 9, 2013

Ariad's Ponatinib Runs Into Big Trouble

Email This Entry

Posted by Derek

Just a note, in case any investors didn't realize it: no, drugs (and a drug companies) are not out of the woods after a compound has been approved and is on the market. Take a look at what's happening to Ariad and their BCR-ABL compound Iclusig (ponatinib). This is used to treat patients that have become resistant to Gleevec, and it's a very big deal for both those patients and for Ariad as a company.

But the percentage of patients on the drug showing serious complications from blood clots has been rising, and that's prompted a number of moves: enrollment in further clinical trials is on hold, dosages are being lowered for current patients, and the product's label is being changed to add warnings of cardiovascular effects. If you're wondering how this affects Ariad as a whole, well, the stock is down 66% in premarket trading as I write. . .

Comments (7) + TrackBacks (0) | Category: Regulatory Affairs | Toxicology


1. anon8 on October 9, 2013 10:12 AM writes...

These are difficult times for many companies, and then on top you hear this!

Permalink to Comment

2. Reverend J on October 9, 2013 10:44 AM writes...

Hmmmmm....I guess they won't be getting back to me about my job application now...

Permalink to Comment

3. Anonymous on October 9, 2013 11:29 AM writes...

@2: The HR guys at Ariad are idiots, so they've probably lost your applicafion anyway.

Permalink to Comment

4. anon the II on October 9, 2013 2:05 PM writes...

@ #1

That's interesting. The President of Global R&D at Jiangsu Hengrui Medicine is a former Lilly employee.

Permalink to Comment

5. Dr Able Lawrence on October 9, 2013 11:23 PM writes...

After the publication of a case report of dramatic response to Gleevec in a patient with Pulmonary hypertension, a colleague and I prescribed it off label for two patients (one pt by each of us) with advanced Pulmonary hypertension. Both patients developed severe neutropenia with just 200mg (half the starting dose for CML). So abelson kinase is not something to mess around with. In patients with CML, the mutant stem cell clone is hyper active and it is fine to inhibit it. May be more potent inhibitors can have multiple effects since abelson kinase interacts with an obscene number of other signalling proteins.

Permalink to Comment

7. Anonymous on October 10, 2013 1:05 AM writes...

#4, It is correct!
One of two, Dr. Cao already listed himself as VP of HengRui in Linkedin, while also working at Lilly (also listed in Linkedin)?? What a stupidity!!

It's a real shame for Hengrui's R&D head/President, Dr. Zhang, also former Lilly's.. He's toasted apparently.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry